Drugs that contain Peginesatide Acetate

1. Drug name - OMONTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(1 year, 7 months from now)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

CN1823088B TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
Jul, 2015

(7 years ago)

CN1823088A TAKEDA PHARMS USA Generating New Peptide Receptor Binding
Jul, 2015

(7 years ago)

CN1823087A TAKEDA PHARMS USA Generating New Peptide Receptor Binding
Apr, 2019

(3 years ago)

CN100441595C TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
Apr, 2019

(3 years ago)

IN200502499P2 TAKEDA PHARMS USA A Peptide Dimer
May, 2024

(1 year, 7 months from now)

IN224732B TAKEDA PHARMS USA A Peptide Dimer
May, 2024

(1 year, 7 months from now)

IN200502493P2 TAKEDA PHARMS USA A Peptide Cross-Reference To Related Applications
May, 2024

(1 year, 7 months from now)

IN228387B TAKEDA PHARMS USA A Peptide
May, 2024

(1 year, 7 months from now)

EP1629007B1 TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1625156B1 TAKEDA PHARMS USA Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1629007A2 TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1625156A2 TAKEDA PHARMS USA Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses Jun, 2026

(3 years from now)

US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses Jun, 2026

(3 years from now)

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.